Physician profile
Nicole E Hoover
NPI 1043660392
$4,206.00
in general payments reported to CMS, 2019-2025
22 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $474 · 2022: $566 · 2023: $877 · 2024: $1,648 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,165.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $850.30 | 2021-2024 | Optis, Mitraclip, Absolute Pro |
| Edwards Lifesciences Corporation | $678.40 | 2023-2025 | Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $610.18 | 2022-2025 | Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $399.88 | 2022-2025 | Lifevest |
| Amgen INC. | $314.58 | 2022-2025 | Repatha, Repatha |
| Medtronic, INC. | $245.44 | 2021-2024 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $224.14 | 2022-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $201.94 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $154.16 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $123.45 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $101.42 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $77.70 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $34.02 | 2022-2023 | Andexxa |
| Acist Medical Systems, INC. | $30.76 | 2025 | |
| Genzyme Corporation | $26.08 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $23.20 | 2024 | Zio At Patch |
| Philips North America LLC | $22.98 | 2022 | |
| Impulse Dynamics (USA) INC. | $21.24 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.17 | 2024 | Onpattro |
| Janssen Pharmaceuticals, INC | $17.22 | 2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $14.88 | 2023 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $13.86 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Hoover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.